Form 4: Theravance Biopharma SVP, General Counsel, and Secretary Reports Share Disposal for Tax Obligations

Brett A. Grimaud, SVP, General Counsel, and Secretary of Theravance Biopharma, Inc., reports disposing of 9,743 ordinary shares to cover tax obligations related to vesting restricted stock units.

Summary

• On May 20, 2025, Brett A. Grimaud, SVP, General Counsel, and Secretary of Theravance Biopharma, Inc., disposed of 9,743 ordinary shares.
• The shares were disposed of to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
• The transaction was conducted with the issuer and did not involve an open market transaction.
• The price per share was $9.45.
• Following the transaction, Grimaud beneficially owns 384,068 ordinary shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard transaction for tax purposes.

Industry Context

This is a routine Form 4 filing, which is common for corporate insiders who have stock-based compensation. It indicates that an executive is managing their tax liabilities related to stock vesting.

Related Party Transactions

• The share withholding transaction was with the issuer to satisfy tax obligations.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine disposal of shares for tax purposes.

Key Dates

Keywords

Theravance Biopharma, TBPH, Form 4, Insider Trading, Share Disposal, Tax Obligations, Restricted Stock Units, Brett A. Grimaud, Beneficial Ownership